Study of a new drug for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have a confirmed diagnosis of prostate cancer (adenocarcinoma) that has spread to bones or soft tissue.
- Your cancer has worsened even after at least one newer hormone therapy (like abiraterone or enzalutamide) and, for the dose-escalation part, you have also had at least one line of chemotherapy (like docetaxel).
- You are currently on hormone therapy that has lowered your testosterone to castrate levels (as confirmed by a blood test).
- You are generally well enough to perform daily activities (ECOG score 0 or 1).
- You are willing to use contraception and not donate sperm for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This study tests a new investigational medicine for prostate cancer that has spread and is no longer controlled by standard hormone therapy. The drug may work by targeting a protein on cancer cells, and the trial will check if it can shrink the cancer or slow its growth.
This study tests a new oral tablet (HRS-7525) for men with advanced prostate cancer that has spread. It aims to see if the drug is safe and effective, and may offer a new treatment option for those who have not responded to standard therapies.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new targeted therapy (DEC003M) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to see if this treatment is safe and helps shrink tumors.
This study tests an experimental drug, alone or with other treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if it can shrink tumors or slow the disease.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.